Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

High Riding Prostate: Epidemiology of Genitourinary Injury in Motorcyclists from a UK Register of over 12,000 Victims.

Autor: Moss, Basil F., Moss, Catherine E., Dervin, Patrick, Lawrence, Thomas, Jones, Sophie, Thomas, Stephen

Publikováno v: Current Urology; 2020, Vol. 14 Issue 2, p105-112, 8p

A novel allosteric activator of free fatty acid 2 receptor displays unique Gi-functional bias

Autor: Bolognini, Daniele, Moss, Catherine E., Nilsson, Karolina, Petersson, Annika U., Donnelly, Iona, Sergeev, Eugenia, König, Gabriele M., Kostenis, Evi, Kurowska-Stolarska, Mariola, Miller, Ashley, Dekker, Niek, Tobin, Andrew B., Milligan, Graeme

The short chain fatty acid receptor FFA2 is able to stimulate signalling via both Gi and Gqv/G11-promoted pathways. These pathways are believed to control distinct physiological endpoints but FFA2 receptor ligands appropriate to test this hypothesis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::4bc93ff86ee906091665ecdccc40bcce
https://eprints.gla.ac.uk/111475/1/111475.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias.

Autor: Bolognini D; From the Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom., Moss CE; From the Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom, the Medical Research Council Toxicology Unit, University of Leicester, Leicester LE1 9HN, United Kingdom., Nilsson K; the Cardiovascular and Metabolic Diseases., Petersson AU; Respiratory, Inflammatory and Autoimmune Diseases Innovative Medicines and Early Development Biotech Unit, Department of Medicinal Chemistry, and., Donnelly I; the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom., Sergeev E; From the Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom., König GM; Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany, and., Kostenis E; the Molecular, Cellular and Pharmacobiology Section., Kurowska-Stolarska M; the Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom., Miller A; the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom., Dekker N; the Discovery Sciences, Reagents and Assay Development, AstraZeneca, Mölndal, Pepparedsleden 1, SE-431 83, Mölndal, Sweden., Tobin AB; From the Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom, the Medical Research Council Toxicology Unit, University of Leicester, Leicester LE1 9HN, United Kingdom., Milligan G; From the Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom, Graeme.Milligan@glasgow.ac.uk.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2016 Sep 02; Vol. 291 (36), pp. 18915-31. Date of Electronic Publication: 2016 Jul 05.